Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.06 USD | +3.31% | +4.33% | +7.10% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company sustains low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.10% | 1.65B | D+ | ||
+4.06% | 70.44B | A | ||
+10.97% | 8.94B | A- | ||
-14.44% | 4.75B | A- | ||
+41.60% | 4.5B | - | ||
+5.96% | 3.85B | B- | ||
+23.46% | 2.38B | B | ||
-19.32% | 2.34B | C- | ||
-27.04% | 2.2B | - | ||
+7.97% | 1.96B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SUPN Stock
- Ratings Supernus Pharmaceuticals, Inc.